India's Dr. Reddy's Is Set To Launch A Fourth Biosimilar - Pegfilgrastim
This article was originally published in The Pink Sheet Daily
Executive Summary
With filgrastim, rituximab and darbepoetin alfa already under its belt, Dr. Reddy's says it has seven more products - the bulk of which are thought to be copies of established monoclonal antibodies - in early development and preclinical testing.
You may also be interested in...
Dr. Reddy's Launches World's First Aranesp Biosimilar In India, Vows To Bring Out More
MUMBAI - Dr. Reddy's Labs has become the world's first company to launch a generic version of Amgen's erythropoiesis-stimulating agent Aranesp (darbepoetin alfa). The biosimilar, called Cresp, has been approved in India for the treatment of anemia due to chronic kidney disease and anemia due to chemotherapy, Dr. Reddy's announced Aug. 9
After Launching First Pegylated GCSF, Intas Biopharma Examines Technology For Pegylated Erythropoietin
MUMBAI - Ahmedabad, India-based biotech firm Intas Biopharma is looking at commencing research on a generic form of pegylated erythropoietin
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.